CHRS - Coherus Biosciences Inc Stock Price, Fair Value and News

2.07USD0.00 (0.00%)Delayed as of 22 Apr 2024, 11:56 am ET

Market Summary

USD2.070.00

Delayedas of 22 Apr 2024, 11:56 am

0.00%

CHRS Stock Price

View Fullscreen

CHRS RSI Chart

CHRS Valuation

Market Cap

233.3M

Price/Earnings (Trailing)

-0.98

Price/Sales (Trailing)

0.91

EV/EBITDA

-0.67

Price/Free Cashflow

-1.33

CHRS Price/Sales (Trailing)

CHRS Profitability

EBT Margin

-92.62%

Return on Equity

122.99%

Return on Assets

-37.78%

Free Cashflow Yield

-75.08%

CHRS Fundamentals

CHRS Revenue

Revenue (TTM)

257.2M

Rev. Growth (Yr)

101.81%

Rev. Growth (Qtr)

22.74%

CHRS Earnings

Earnings (TTM)

-237.9M

Earnings Growth (Yr)

-35.3%

Earnings Growth (Qtr)

-100.94%

Breaking Down CHRS Revenue

52 Week Range

2.058.33

(Low)(High)

Last 7 days

-8.1%

Last 30 days

-17.3%

Last 90 days

-16.0%

Trailing 12 Months

-74.3%

How does CHRS drawdown profile look like?

CHRS Financial Health

Current Ratio

1.43

CHRS Investor Care

Shares Dilution (1Y)

41.58%

Diluted EPS (TTM)

-2.57

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	183.4M	181.9M	211.1M	257.2M
2022	303.6M	276.1M	239.1M	211.0M
2021	442.7M	394.6M	363.6M	326.6M
2020	435.1M	487.4M	489.3M	475.8M
2019	284.9M	308.6M	332.3M	356.1M
2017	0	213.8M	237.5M	261.2M
2016	36.6M	43.8M	199.5M	190.1M
2015	33.3M	35.2M	26.3M	30.0M
2014	5.8M	10.3M	25.8M	31.1M
2013	2.1M	2.3M	2.5M	2.8M
2012	0	0	0	1.9M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Coherus Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 09, 2024	wahlstrom mats	gifted	-	-	-99,988	-
Feb 09, 2024	wahlstrom mats	gifted	-	-	99,988	-
Feb 01, 2024	wahlstrom mats	acquired	100,000	1.667	59,988	-
Jan 20, 2024	lanfear dennis m	sold (taxes)	-27,371	2.44	-11,218	president & ceo
Jan 20, 2024	mcmichael bryan j	sold (taxes)	-4,165	2.44	-1,707	see remarks
Jan 20, 2024	reider paul	sold (taxes)	-11,843	2.44	-4,854	chief commercial officer
Jan 07, 2024	mcmichael bryan j	sold (taxes)	-4,899	2.87	-1,707	see remarks
Jan 04, 2024	reider paul	sold (taxes)	-6,643	2.92	-2,275	chief commercial officer
Jan 04, 2024	lanfear dennis m	sold (taxes)	-34,400	2.92	-11,781	president & ceo
Dec 31, 2023	stilwell mcdavid	sold (taxes)	-61,405	3.33	-18,440	chief financial officer

Which funds bought or sold CHRS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	Allspring Global Investments Holdings, LLC	added	26.69	-2,489	24,966	-%
Apr 18, 2024	SteelPeak Wealth, LLC	unchanged	-	-64,860	164,910	0.01%
Apr 15, 2024	Legato Capital Management LLC	unchanged	-	-92,336	234,767	0.03%
Apr 15, 2024	Security National Bank	sold off	-100	-173	-	-%
Apr 12, 2024	Bridge City Capital, LLC	added	0.78	-288,302	753,768	0.28%
Apr 11, 2024	INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC	reduced	-2.51	-42,368	100,123	0.01%
Apr 11, 2024	RFG Advisory, LLC	new	-	141,512	141,512	-%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Apr 05, 2024	GAMMA Investing LLC	reduced	-14.12	-203	4,273	-%
Apr 05, 2024	LOS ANGELES CAPITAL MANAGEMENT LLC	added	43.41	13,331	468,942	-%

Are Funds Buying or Selling CHRS?

Are funds buying CHRS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CHRS

No. of Funds

Unveiling Coherus Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	citadel advisors llc	1.6%	6	SC 13G/A
Feb 14, 2024	alliancebernstein l.p.	0.1%	156,000	SC 13G/A
Feb 13, 2024	vanguard group inc	9.30%	10,357,412	SC 13G/A
Jan 24, 2024	blackrock inc.	10.8%	12,074,695	SC 13G/A
Jan 22, 2024	state street corp	1.85%	2,064,326	SC 13G/A
Dec 07, 2023	jpmorgan chase & co	0.1%	124,796	SC 13G/A
Oct 06, 2023	blackrock inc.	10.9%	11,645,835	SC 13G/A
May 19, 2023	citadel advisors llc	6.1%	6	SC 13G
Feb 14, 2023	perceptive advisors llc	0%	0	SC 13G/A
Feb 14, 2023	alliancebernstein l.p.	8.0%	6,217,558	SC 13G/A

Recent SEC filings of Coherus Biosciences Inc

View All Filings

Date Filed	Form Type	Document
Apr 15, 2024	ARS	ARS
Apr 15, 2024	DEF 14A	DEF 14A
Apr 15, 2024	DEFA14A	DEFA14A
Mar 28, 2024	S-8	Employee Benefits Plan
Mar 15, 2024	10-K	Annual Report
Mar 13, 2024	8-K	Current Report
Mar 04, 2024	8-K	Current Report
Feb 22, 2024	3	Insider Trading
Feb 22, 2024	4	Insider Trading
Feb 22, 2024	8-K	Current Report

Peers (Alternatives to Coherus Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-1.66%	-28.18%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.46%	-28.84%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	4.57%	-8.46%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-10.11%	-29.11%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.66	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-13.81%	-4.67%	-13.45	11.89	440.80%	-27.84%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.22	3.82	40.45%	71.62%
ARWR	2.8B	240.7M	-20.67%	-25.33%	-9.32	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-17.39%	-51.52%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-0.38%	387.14%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-10.29%	-2.81%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	59.81%	33.59%	-0.22	2.14	-13.45%	66.37%

Coherus Biosciences Inc News

Latest updates

Coherus Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2017Q4
Revenue	22.7%	91,524,000	74,568,000	58,716,000	32,436,000	45,352,000	45,424,000	60,151,000	60,115,000	73,371,000	82,503,000	87,643,000	83,034,000	110,419,000	113,551,000	135,674,000	116,180,000	123,871,500	111,684,000	83,400,000	37,100,000	28,036,000
Costs and Expenses	50.5%	160,429,000	106,574,000	93,259,000	100,181,000	96,845,000	125,873,000	104,164,000	141,040,000	112,918,000	115,290,000	111,807,000	250,394,000	93,994,000	79,835,000	70,364,000	75,312,000	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	79,835,000	70,364,000	75,312,000	78,823,000	59,843,000	55,940,000	53,697,000	46,466,000
S&GA Expenses	2.6%	49,494,000	48,224,000	45,144,000	49,153,000	53,621,000	44,831,000	51,276,000	48,753,000	50,052,000	39,925,000	40,345,000	39,391,000	37,693,000	31,984,000	34,052,000	35,350,000	36,070,000	31,828,000	36,456,000	32,683,000	-
R&D Expenses	2.8%	26,368,000	25,647,000	23,267,000	34,154,000	29,022,000	45,808,000	41,611,000	82,917,000	50,762,000	54,085,000	54,766,000	203,492,000	44,628,000	38,851,000	26,173,000	33,107,000	34,948,000	21,568,000	18,883,000	18,789,000	-
EBITDA Margin	8.7%	-0.75	-0.83	-1.23	-1.28	-1.21	-1.03	-0.72	-0.59	-0.80	-0.56	-0.35	-0.11	-	-	-	-	-	-	-	-	-
Interest Expenses	3.4%	10,619,000	10,268,000	9,943,000	9,712,000	9,385,000	7,540,000	6,580,000	8,969,000	5,793,000	5,771,000	5,747,000	5,648,000	5,671,000	5,656,000	5,408,000	4,431,000	4,483,000	4,469,000	4,433,000	4,216,000	-
Income Taxes	100.0%	-	-380,000	-	-	-	-	-	-	-	-	-	-	1,049,500	200,000	1,294,000	933,000	2,066,500	800,000	51,000	-	-
Earnings Before Taxes	-99.0%	-79,653,000	-40,021,000	-42,869,000	-75,729,000	-58,870,000	-86,650,000	-50,150,000	-96,084,000	-45,725,000	-38,528,000	-29,900,000	-172,947,000	10,760,500	28,116,000	60,325,000	36,505,000	41,271,000	47,890,000	23,618,000	-20,004,000	-
EBT Margin	10.1%	-0.93	-1.03	-1.45	-1.48	-1.38	-1.17	-0.83	-0.69	-0.88	-0.63	-0.42	-0.17	-	-	-	-	-	-	-	-	-
Net Income	-100.9%	-79,653,000	-39,641,000	-42,869,000	-75,729,000	-58,870,000	-86,650,000	-50,150,000	-96,084,000	-45,725,000	-38,528,000	-29,900,000	-172,947,000	9,708,000	27,933,000	59,031,000	35,572,000	39,227,000	47,043,000	23,567,000	-20,004,000	-
Net Income Margin	10.1%	-0.92	-1.03	-1.45	-1.48	-1.38	-1.17	-0.83	-0.69	-0.88	-0.64	-0.42	-0.17	-	-	-	-	-	-	-	-	-
Free Cashflow	76.1%	-12,971,000	-54,300,000	-39,015,000	-68,884,000	-100,040,000	-37,546,000	-50,917,000	-54,660,000	-52,790,000	13,450,000	-603,000	1,222,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	7.8%	630	584	470	402	481	551	546	593	679	742	740	693	842	804	757	467	409	327	240	186	99.00
Current Assets	7.0%	476	444	385	316	381	448	447	512	602	673	660	617	767	727	676	395	343	276	206	159	84.00
Cash Equivalents	28.2%	103	80.00	73.00	16.00	64.00	287	275	326	417	361	330	259	541	292	225	193	178	165	106	82.00	72.00
Inventory	-6.3%	63.00	67.00	64.00	49.00	39.00	28.00	32.00	37.00	38.00	38.00	40.00	52.00	44.00	35.00	27.00	16.00	10.00	8.00	4.00	2.00	2.00
Net PPE	-15.7%	5.00	6.00	7.00	8.00	9.00	10.00	10.00	8.00	8.00	-	-	-	10.00	-	10.00	7.00	6.00	6.00	6.00	6.00	7.00
Goodwill	-	1.00	-	-	-	1.00	-	-	-	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	14.7%	823	717	644	599	618	648	569	581	582	611	583	566	561	548	543	309	304	271	244	225	138
Current Liabilities	38.4%	332	240	169	123	139	171	141	154	165	320	287	258	146	133	130	119	115	83.00	61.00	41.00	33.00
Shareholder's Equity	-Infinity%	-193	-	-	-	-137	-	-	13.00	98.00	131	156	128	281	256	213	157	105	56.00	0.00	-	947
Retained Earnings	-5.3%	-1,579	-1,499	-1,460	-1,417	-1,341	-1,282	-1,196	-1,145	-1,049	-1,004	-965	-935	-762	-772	-800	-859	-895	-934	-981	-1,004	-984
Additional Paid-In Capital	1.4%	1,386	1,367	1,286	1,221	1,204	1,186	1,174	1,159	1,148	1,135	1,122	1,064	1,044	1,028	1,014	1,017	1,001	991	978	967	947
Shares Outstanding	2.8%	112	109	94.00	80.00	79.00	78.00	78.00	77.00	75.00	75.00	76.00	73.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	324	-	-	-	444	-	-	-	837	-	-	-	900	-	-	-	1,400	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	76.2%	-12,937	-54,300	-38,915	-68,732	-99,953	-37,089	-50,037	-54,045	-52,322	13,711	-188	1,367	33,124	47,353	60,191	13,477	17,710	54,951	12,677	-56,983	-47,363
Share Based Compensation	8.5%	10,798	9,953	10,077	12,282	11,726	12,282	13,850	12,879	10,946	11,939	11,595	16,884	9,873	9,307	9,425	9,555	7,272	8,833	7,992	9,494	8,827
Cashflow From Investing	-30.4%	35,203	50,546	41,365	17,526	-129,898	-457	-880	-35,615	107,490	15,990	23,585	-285,475	210,056	16,407	-239,248	-1,616	-6,062	-289	8,818	-15,199	15,786
Cashflow From Financing	-96.7%	366	11,105	54,325	3,804	6,593	48,867	721	-1,855	1,487	1,101	46,852	2,439	5,513	4,088	210,422	3,923	1,200	3,683	3,010	81,477	2,593

CHRS Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue:
Net revenue	$ 257,244	$ 211,042	$ 326,551
Costs and expenses:
Cost of goods sold	158,992	70,083	57,591
Research and development	109,436	199,358	363,105
Selling, general and administrative	192,015	198,481	169,713
Total costs and expenses	460,443	467,922	590,409
Loss from operations	(203,199)	(256,880)	(263,858)
Interest expense	(40,542)	(32,474)	(22,959)
Loss on debt extinguishment		(6,222)
Other income (expense), net	5,469	3,822	(283)
Loss before income taxes	(238,272)	(291,754)	(287,100)
Income tax provision (benefit)	(380)	0	0
Net loss	$ (237,892)	$ (291,754)	$ (287,100)
Net loss per share:
Basic (In dollar per share)	$ (2.53)	$ (3.76)	$ (3.81)
Diluted (In dollar per share)	$ (2.53)	$ (3.76)	$ (3.81)
Weighted-average number of shares used in computing basic and diluted net loss per share:
Basic (In shares)	94,162,637	77,630,020	75,449,632
Diluted (In shares)	94,162,637	77,630,020	75,449,632

CHRS Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 102,891	$ 63,547
Investments in marketable securities	14,857	128,134
Trade receivables, net	260,522	109,964
Inventory	62,605	38,791
Prepaid manufacturing	23,657	17,880
Other prepaids and current assets	11,099	22,918
Total current assets	475,631	381,234
Property and equipment, net	5,119	8,754
Inventory, non-current	67,495	76,260
Intangible assets, net	71,673	5,931
Other assets, non-current	9,686	8,668
Total assets	629,604	480,847
Current liabilities:
Accounts payable	35,219	11,526
Accrued rebates, fees and reserves	169,645	54,461
Accrued compensation	21,521	22,610
Accrued and other current liabilities	105,386	50,097
Total current liabilities	331,771	138,694
Term loans	246,481	245,483
Convertible notes	226,888	225,575
Lease liabilities, non-current	5,328	5,046
Other liabilities, non-current	12,561	3,467
Total liabilities	823,029	618,265
Commitments and contingencies (Note 9)
Stockholders' deficit:
Common stock ($0.0001 par value; shares authorized: 300,000,000; shares issued and outstanding: 112,215,260 and 78,851,516 at December 31, 2023 and 2022, respectively)	11	8
Additional paid-in capital	1,386,312	1,204,431
Accumulated other comprehensive loss	(248)	(249)
Accumulated deficit	(1,579,500)	(1,341,608)
Total stockholders' deficit	(193,425)	(137,418)
Total liabilities and stockholders' deficit	$ 629,604	$ 480,847

About Coherus Biosciences Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

CEO	Mr. Dennis M. Lanfear
WEBSITE	coherus.com
INDUSTRY	Biotechnology
EMPLOYEES	294

Coherus Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Coherus Biosciences Inc? What does CHRS stand for in stocks?

CHRS is the stock ticker symbol of Coherus Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Coherus Biosciences Inc (CHRS)?

As of Fri Apr 19 2024, market cap of Coherus Biosciences Inc is 233.32 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CHRS stock?

You can check CHRS's fair value in chart for subscribers.

What is the fair value of CHRS stock?

You can check CHRS's fair value in chart for subscribers. The fair value of Coherus Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Coherus Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CHRS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Coherus Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether CHRS is over valued or under valued. Whether Coherus Biosciences Inc is cheap or expensive depends on the assumptions which impact Coherus Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CHRS.

What is Coherus Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, CHRS's PE ratio (Price to Earnings) is -0.98 and Price to Sales (PS) ratio is 0.91. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CHRS PE ratio will change depending on the future growth rate expectations of investors.